374 related articles for article (PubMed ID: 7527817)
1. A peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitopes that induces high titers of neutralizing antibodies.
Baba E; Nakamura M; Ohkuma K; Kira J; Tanaka Y; Nakano S; Niho Y
J Immunol; 1995 Jan; 154(1):399-412. PubMed ID: 7527817
[TBL] [Abstract][Full Text] [Related]
2. Multiple neutralizing B-cell epitopes of human T-cell leukemia virus type 1 (HTLV-1) identified by human monoclonal antibodies. A basis for the design of an HTLV-1 peptide vaccine.
Baba E; Nakamura M; Tanaka Y; Kuroki M; Itoyama Y; Nakano S; Niho Y
J Immunol; 1993 Jul; 151(2):1013-24. PubMed ID: 7687611
[TBL] [Abstract][Full Text] [Related]
3. Identification of new epitopes recognized by human monoclonal antibodies with neutralizing and antibody-dependent cellular cytotoxicity activities specific for human T cell leukemia virus type 1.
Kuroki M; Nakamura M; Itoyama Y; Tanaka Y; Shiraki H; Baba E; Esaki T; Tatsumoto T; Nagafuchi S; Nakano S
J Immunol; 1992 Aug; 149(3):940-8. PubMed ID: 1378869
[TBL] [Abstract][Full Text] [Related]
4. Identification of a neutralization epitope on the envelope gp46 antigen of human T cell leukemia virus type I and induction of neutralizing antibody by peptide immunization.
Tanaka Y; Zeng L; Shiraki H; Shida H; Tozawa H
J Immunol; 1991 Jul; 147(1):354-60. PubMed ID: 1711082
[TBL] [Abstract][Full Text] [Related]
5. Sequence analysis of an immunogenic and neutralizing domain of the human T-cell lymphoma/leukemia virus type I gp46 surface membrane protein among various primate T-cell lymphoma/leukemia virus isolates including those from a patient with both HTLV-I-associated myelopathy and adult T-cell leukemia.
Sherman MP; Dube S; Spicer TP; Kane TD; Love JL; Saksena NK; Iannone R; Gibbs CJ; Yanagihara R; Dube DK
Cancer Res; 1993 Dec; 53(24):6067-73. PubMed ID: 8261424
[TBL] [Abstract][Full Text] [Related]
6. Antibodies to the envelope glycoprotein of human T cell leukemia virus type 1 robustly activate cell-mediated cytotoxic responses and directly neutralize viral infectivity at multiple steps of the entry process.
Kuo CW; Mirsaliotis A; Brighty DW
J Immunol; 2011 Jul; 187(1):361-71. PubMed ID: 21646298
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity and conformational properties of an N-linked glycosylated peptide epitope of human T-lymphotropic virus type 1 (HTLV-I).
Conrad SF; Byeon IJ; DiGeorge AM; Lairmore MD; Tsai MD; Kaumaya PT
Biomed Pept Proteins Nucleic Acids; 1995; 1(2):83-92. PubMed ID: 9346859
[TBL] [Abstract][Full Text] [Related]
8. Induction of CD4+, human T lymphotropic virus type-1-specific cytotoxic T lymphocytes from patients with HAM/TSP. Recognition of an immunogenic region of the gp46 envelope glycoprotein of human T lymphotropic virus type-1.
Jacobson S; Reuben JS; Streilein RD; Palker TJ
J Immunol; 1991 Feb; 146(4):1155-62. PubMed ID: 1704032
[TBL] [Abstract][Full Text] [Related]
9. Mapping of immunogenic regions of human T cell leukemia virus type I (HTLV-I) gp46 and gp21 envelope glycoproteins with env-encoded synthetic peptides and a monoclonal antibody to gp46.
Palker TJ; Tanner ME; Scearce RM; Streilein RD; Clark ME; Haynes BF
J Immunol; 1989 Feb; 142(3):971-8. PubMed ID: 2563272
[TBL] [Abstract][Full Text] [Related]
10. Chimeric synthetic peptides containing two immunodominant epitopes from the envelope gp46 and the transmembrane gp21 glycoproteins of HTLV-I virus.
Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
Biochem Biophys Res Commun; 2001 Nov; 289(1):1-6. PubMed ID: 11708767
[TBL] [Abstract][Full Text] [Related]
11. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
[TBL] [Abstract][Full Text] [Related]
12. Influence of amino acid substitutions on antigenicity of immunodominant regions of the HTLV type I envelope surface gylcoprotein: a study using monoclonal antibodies raised against relevant peptides.
Londos-Gagliardi D; Jauvin V; Armengaut MH; Astier-Gin T; Goetz M; Huet S; Guillemain BJ
AIDS Res Hum Retroviruses; 1999 Jul; 15(10):909-20. PubMed ID: 10408728
[TBL] [Abstract][Full Text] [Related]
13. Identification of type-specific linear epitopes in the glycoproteins gp46 and gp21 of human T-cell leukemia viruses type I and type II using synthetic peptides.
Horal P; Hall WW; Svennerholm B; Lycke J; Jeansson S; Rymo L; Kaplan MH; Vahlne A
Proc Natl Acad Sci U S A; 1991 Jul; 88(13):5754-8. PubMed ID: 1712105
[TBL] [Abstract][Full Text] [Related]
14. Chimeric synthetic peptides from the envelope (gp46) and the transmembrane (gp21) glycoproteins for the detection of antibodies to human T-cell leukemia virus type II.
Hernández Marin M; Castellanos Pentón P; Márquez Bocalandro Y; Pozo Peña L; Díaz Navarro J; González López LJ
Biochem Biophys Res Commun; 2001 Nov; 289(1):7-12. PubMed ID: 11708768
[TBL] [Abstract][Full Text] [Related]
15. Glycosylation-dependent peptide antigenic determinants of env gp46 HTLV-1.
Kaumaya PT; Conrad SF; DiGeorge AM; Lairmore MD
Leukemia; 1995 Oct; 9 Suppl 1():S133-8. PubMed ID: 7475306
[TBL] [Abstract][Full Text] [Related]
16. Human T-cell leukemia virus type-I (HTLV-I)-specific T-cell responses detected using three-divided glutathione-S-transferase (GST)-Tax fusion proteins.
Kurihara K; Shimizu Y; Takamori A; Harashima N; Noji M; Masuda T; Utsunomiya A; Okamura J; Kannagi M
J Immunol Methods; 2006 Jun; 313(1-2):61-73. PubMed ID: 16723135
[TBL] [Abstract][Full Text] [Related]
17. Antigenicity of chimeric synthetic peptides based on HTLV-1 antigens and the impact of epitope orientation.
Hernández M; Selles ME; Pozo Peña L; Gómez I; Melchor A
Biochem Biophys Res Commun; 2000 Oct; 276(3):1085-8. PubMed ID: 11027594
[TBL] [Abstract][Full Text] [Related]
18. The humoral immune response to human T-cell lymphotropic virus type 1 envelope glycoprotein gp46 is directed primarily against conformational epitopes.
Hadlock KG; Rowe J; Foung SK
J Virol; 1999 Feb; 73(2):1205-12. PubMed ID: 9882322
[TBL] [Abstract][Full Text] [Related]
19. Association between maternal antibodies to the external envelope glycoprotein and vertical transmission of human T-lymphotropic virus type I. Maternal anti-env antibodies correlate with protection in non-breast-fed children.
Hino S; Katamine S; Miyamoto T; Doi H; Tsuji Y; Yamabe T; Kaplan JE; Rudolph DL; Lal RB
J Clin Invest; 1995 Jun; 95(6):2920-5. PubMed ID: 7769134
[TBL] [Abstract][Full Text] [Related]
20. Characterization of a B-cell immunodominant epitope of human T-lymphotropic virus type 1 (HTLV-I) envelope gp46.
Lairmore MD; Rudolph DL; Roberts BD; Dezzutti CS; Lal RB
Cancer Lett; 1992 Sep; 66(1):11-20. PubMed ID: 1360328
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
